135 related articles for article (PubMed ID: 31514959)
41. Intraductal papillary mucinous neoplasms of the pancreas with concurrent pancreatic and periampullary neoplasms.
Sahora K; Crippa S; Zamboni G; Ferrone C; Warshaw AL; Lillemoe K; Mino-Kenudson M; Falconi M; Fernandez-del Castillo C
Eur J Surg Oncol; 2016 Feb; 42(2):197-204. PubMed ID: 26687069
[TBL] [Abstract][Full Text] [Related]
42. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
[TBL] [Abstract][Full Text] [Related]
43. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
[TBL] [Abstract][Full Text] [Related]
44. Pancreatic resection for intraductal papillary mucinous neoplasm- a thirteen-year single center experience.
Marsoner K; Haybaeck J; Csengeri D; Waha JE; Schagerl J; Langeder R; Mischinger HJ; Kornprat P
BMC Cancer; 2016 Nov; 16(1):844. PubMed ID: 27809876
[TBL] [Abstract][Full Text] [Related]
45. Early detection and biomarkers in pancreatic cancer.
Misek DE; Patwa TH; Lubman DM; Simeone DM
J Natl Compr Canc Netw; 2007 Nov; 5(10):1034-41. PubMed ID: 18053427
[TBL] [Abstract][Full Text] [Related]
46. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
47. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.
Pea A; Yu J; Rezaee N; Luchini C; He J; Dal Molin M; Griffin JF; Fedor H; Fesharakizadeh S; Salvia R; Weiss MJ; Bassi C; Cameron JL; Zheng L; Scarpa A; Hruban RH; Lennon AM; Goggins M; Wolfgang CL; Wood LD
Ann Surg; 2017 Jul; 266(1):133-141. PubMed ID: 27433916
[TBL] [Abstract][Full Text] [Related]
48. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
[TBL] [Abstract][Full Text] [Related]
49. Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms.
Kamata K; Takenaka M; Minaga K; Omoto S; Miyata T; Yamao K; Imai H; Nakai A; Tanaka H; Chiba Y; Watanabe T; Sakurai T; Nishida N; Chikugo T; Matsumoto I; Takeyama Y; Kitano M; Kudo M
Dig Endosc; 2018 Sep; 30(5):659-666. PubMed ID: 29675938
[TBL] [Abstract][Full Text] [Related]
50. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance.
Canto MI; Almario JA; Schulick RD; Yeo CJ; Klein A; Blackford A; Shin EJ; Sanyal A; Yenokyan G; Lennon AM; Kamel IR; Fishman EK; Wolfgang C; Weiss M; Hruban RH; Goggins M
Gastroenterology; 2018 Sep; 155(3):740-751.e2. PubMed ID: 29803839
[TBL] [Abstract][Full Text] [Related]
51. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
52. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution.
Napoli C; Sperandio N; Lawlor RT; Scarpa A; Molinari H; Assfalg M
J Proteome Res; 2012 Feb; 11(2):1274-83. PubMed ID: 22066465
[TBL] [Abstract][Full Text] [Related]
53. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma.
Rezaee N; Barbon C; Zaki A; He J; Salman B; Hruban RH; Cameron JL; Herman JM; Ahuja N; Lennon AM; Weiss MJ; Wood LD; Wolfgang CL
HPB (Oxford); 2016 Mar; 18(3):236-46. PubMed ID: 27017163
[TBL] [Abstract][Full Text] [Related]
54. Development of novel diagnostic system for pancreatic cancer, including early stages, measuring mRNA of whole blood cells.
Sakai Y; Honda M; Matsui S; Komori O; Murayama T; Fujiwara T; Mizuno M; Imai Y; Yoshimura K; Nasti A; Wada T; Iida N; Kitahara M; Horii R; Toshikatsu T; Nishikawa M; Okafuji H; Mizukoshi E; Yamashita T; Yamashita T; Arai K; Kitamura K; Kawaguchi K; Takatori H; Shimakami T; Terashima T; Hayashi T; Nio K; Kaneko S;
Cancer Sci; 2019 Apr; 110(4):1364-1388. PubMed ID: 30742728
[TBL] [Abstract][Full Text] [Related]
55. Clinical significance of activin A and myostatin in patients with pancreatic adenocarcinoma and progressive weight loss.
Talar-Wojnarowska R; Wozniak M; Borkowska A; Olakowski M; Malecka-Panas E
J Physiol Pharmacol; 2020 Feb; 71(1):. PubMed ID: 32554845
[TBL] [Abstract][Full Text] [Related]
56. Preoperative maximum standardized uptake value and carbohydrate antigen 19-9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma.
Gu X; Zhou R; Li C; Liu R; Zhao Z; Gao Y; Xu Y
BMC Cancer; 2019 May; 19(1):456. PubMed ID: 31092213
[TBL] [Abstract][Full Text] [Related]
57. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression.
Roch AM; Ceppa EP; Al-Haddad MA; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Ann Surg; 2014 Oct; 260(4):680-8; discussion 688-90. PubMed ID: 25203885
[TBL] [Abstract][Full Text] [Related]
58. Association between the Risk Factors for Pancreatic Ductal Adenocarcinoma and Those for Malignant Intraductal Papillary Mucinous Neoplasm.
Kamata K; Takenaka M; Nakai A; Omoto S; Miyata T; Minaga K; Matsuda T; Yamao K; Imai H; Chiba Y; Sakurai T; Watanabe T; Nishida N; Chikugo T; Matsumoto I; Takeyama Y; Kudo M
Oncology; 2017; 93 Suppl 1():102-106. PubMed ID: 29258117
[TBL] [Abstract][Full Text] [Related]
59. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms.
Yu J; Sadakari Y; Shindo K; Suenaga M; Brant A; Almario JAN; Borges M; Barkley T; Fesharakizadeh S; Ford M; Hruban RH; Shin EJ; Lennon AM; Canto MI; Goggins M
Gut; 2017 Sep; 66(9):1677-1687. PubMed ID: 27432539
[TBL] [Abstract][Full Text] [Related]
60. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
